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Summary Background Alefacept, human LFA-3 ⁄ IgG1 fusion protein, is a novel biological agent currently
being developed for the treatment of chronic plaque psoriasis. Alefacept selectively reduces the
memory-effector T cells that have been implicated in the pathogenesis of the disease; as a result,
alefacept is classified as a therapy that induces remission (so-called ‘remittive’ therapy). In a
previously published randomized, placebo-controlled phase II study of intravenous alefacept in 229
patients with chronic plaque psoriasis, clinical improvement was observed during dosing as well as
in the postdosing follow-up period.
Objectives To assess the remission period following alefacept therapy.
Methods The time before re-treatment was required was measured in patients who were ‘clear’ or
‘almost clear’ of disease according to a physician global assessment at the end of the follow-up
phase.
Results In these patients, responses were sustained for a median of 10 months, and for up to
18 months. No patient reported disease rebound after cessation of alefacept.
Conclusions Alefacept is a biological agent for the treatment of chronic plaque psoriasis that
provides disease-free intervals and time off drug therapy.
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Currently available systemic therapies for chronic
plaque psoriasis are primarily suppressive in nature.
They can produce clinical improvement to clearing
during therapy, but responses are typically of short
duration and may be accompanied by disease rebound
after therapy is withdrawn. Ciclosporin is an example
of a drug in which maintenance therapy is necessary to
sustain a favourable response,1 and there have been
reports of disease rebound or worsening after treatment
is stopped.2,3 In addition to the constant requirement
for drug therapy, patients receiving these suppressive
agents (e.g. ciclosporin, methotrexate) are at risk for
organ toxicities, such as nephrotoxicity and hepato-
toxicity.4–6
Therapies that provide long-lasting remission of
psoriasis are characterized by mechanisms that reduce
T cells in skin lesions.7 Psoralen plus long-wave
ultraviolet (UV) radiation (PUVA), and perhaps UVB,
are the only currently available treatments for psoriasis
that produce a meaningful remission of disease after
therapy is complete.8,9 For PUVA, this effect has been
associated with a significant reduction of tissue-
infiltrating lymphocytes in psoriatic skin.10,11 How-
ever, repeated and long-term use of phototherapy is
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associated with an increased risk of skin cancer.12–14
The limitations of current therapies highlight the need
for safe therapies for psoriasis that increase disease-free
intervals and time off toxic treatments.
Alefacept (currently being developed under the trade
name Amevive; Biogen Inc., Cambridge, MA, U.S.A.)
is a novel and selective biological agent. It is a fully
human LFA-3 ⁄ IgG1 fusion protein that binds CD2
receptors expressed on the surface of T cells and
natural killer (NK) cells.15 CD2 expression is higher on
memory-effector (expressing CD45RO+ markers) CD4+
and CD8+ T cells, which have been strongly implicated
in the pathogenesis of psoriasis,16,17 compared with
naı̈ve T cells that do not express CD45RO.18,19 By
blocking the LFA-3 ⁄ CD2 interaction on T cells, alefa-
cept selectively inhibits T-cell activation and prolifer-
ation.15,20 In addition, the Fc portion of alefacept
interacts with the immunoglobulin receptor FccRIII on
the surface of NK cells, resulting in NK-cell-induced
T-cell apoptosis.21 In vivo, alefacept selectively reduces
circulating memory T cells, which parallels its potential
to induce remission in psoriasis.20,22
In a phase II study of alefacept therapy,22 many
patients showed continued improvement after cessation
of treatment. This finding suggested that assessment of
clinical efficacy at one time point does not fully reflect
the percentage of patients who respond to alefacept;
thus, response rates were determined over the entire
study period. In addition, to quantify the remission
provided by alefacept, the time before patients required
further alefacept therapy was evaluated.
Patients and methods
Alefacept was tested in a randomized, multicentre,
double-blind, placebo-controlled, parallel-group, phase
II study; a detailed description has been published
previously.22 In brief, patients aged 18–70 years with
chronic plaque psoriasis (body surface involvement
‡ 10%, duration of psoriasis > 12 months before entry,
and prior systemic treatment or phototherapy or
candidates for such therapy) were randomized to
receive alefacept 0Æ025, 0Æ075 or 0Æ150 mg kg)1 or
placebo administered as a 30-s intravenous bolus
injection once weekly for 12 weeks. Systemic therapies,
phototherapy or potent topical therapies were not
allowed from 4 weeks before treatment through the
second week after alefacept was discontinued. For
psoriasis of the groin, scalp, palm or soles only,
moderate potency topical corticosteroids, keratolytics,
coal tar or calcipotriol could be used if necessary.
Emollients could be used elsewhere if symptoms
warranted, but not within 12 h of physician evalua-
tion. The institutional review board at each institution
approved the protocol and all patients provided written
informed consent.
Efficacy was measured by changes in Psoriasis Area
and Severity Index (PASI) from baseline and an overall
assessment of disease severity, the physician global
assessment (PGA), in which the treating physician rated
the extent of psoriatic involvement at each visit on a
seven-point scale: 0, clear (no psoriasis); 1, almost clear;
2, mild; 3, mild to moderate; 4, moderate; 5, moderate to
severe; 6, severe. Patients who completed the 12-week
treatment and 12-week follow-up periods were eligible
to receive subsequent courses of alefacept. Re-treatment
with alefacept was initiated when a patient’s disease had
progressed such that the attending physician and the
patient felt that systemic therapy was required. The time
to re-treatment was recorded as the time from the last
dose of alefacept in the phase II study until further
systemic treatment with alefacept was initiated.
Results
In total, 229 patients were enrolled in the phase II
study (59, 57, 55 and 58 in the placebo,
0Æ025 mg kg)1 alefacept, 0Æ075 mg kg)1 alefacept
and 0Æ150 mg kg)1 alefacept groups, respectively),
the results of which have been published previously.22
Baseline demographics and clinical characteristics were
similar among all treatment groups.22,23
Figure 1. Overall response rates: percentage of patients achieving
response criteria over the entire study period (P < 0Æ001 for the
overall treatment difference for each of the three response criteria,
logistic regression). PASI, Psoriasis Area and Severity Index; PGA,
physician global assessment.
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Of the 229 patients, 197 completed the study. The
most common reasons for discontinuing treatment
were worsening of disease and voluntary withdrawal in
the placebo group (17% of patients receiving placebo)
and voluntary withdrawal, being lost to follow-up, and
adverse events in the three alefacept groups combined
(13% of patients receiving alefacept).22 Alefacept was
well tolerated and adverse events were generally mild.
The most common adverse events were pharyngitis,
headache, accidental injury, rhinitis and dizziness.22
Laboratory tests showed no consistent chemical
abnormalities in any group.
Two weeks after treatment, the mean reduction in
PASI was 21% in the placebo group and 38%, 53% and
53% in the 0Æ025 mg kg)1, 0Æ075 mg kg)1 and
0Æ150 mg kg)1 alefacept groups, respectively.22 Over-
all response rates are shown in Figure 1. At the most
effective dose (0Æ075 mg kg)1), three-quarters of
patients achieved a 50% or greater reduction in
PASI, approximately half achieved a 75% or greater
reduction in PASI, and nearly one-third were ‘clear’ or
‘almost clear’ according to the PGA.
Of 148 patients who were assigned to and completed
alefacept therapy, 118 (80%) achieved sufficient
improvement that they required no added therapy for
psoriasis during the initial 12-week post-treatment
follow-up (Fig. 2).22 Two weeks after treatment, 19 of
these patients (16%) were determined to be ‘clear’ or
‘almost clear’ of psoriasis by the PGA, with 16 of the 19
patients (84%) maintaining this level of response
during the 12-week follow-up period. Twelve addi-
tional patients showed continued improvement after
dosing was stopped and, despite having had no
additional psoriasis treatment, they became ‘clear’ or
‘almost clear’ of disease during the 12-week follow-up,
giving a total of 28 patients (24%).22 Of these 28
patients, 26 went on to participate in a subsequent
open-label study; this group of patients did not require
further systemic therapy with alefacept for a median of
10 months (range 6–18).22 There was no correlation
Figure 2. Flow chart of patients who
obtained remissions with alefacept therapy.
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between dose of alefacept and length of remission
(P ¼ 0Æ28, Table 1). Additional courses of alefacept
also provided similar periods of remission.24 There have
been no reports of rapid flares or rebound of psoriasis
after cessation of alefacept therapy.22,24
Discussion
Alefacept, administered once weekly for 12 weeks, is
an effective and well-tolerated agent for patients with
chronic plaque psoriasis.22 Patients showed continued
improvement in psoriasis after the end of the 12-week
treatment course, with substantial improvements in
both PASI scores and PGA over the entire study period.
Importantly, these responses were sustained without
the need for re-treatment with alefacept for up to
18 months in some patients.
Unfortunately, the duration of response for currently
available antipsoriatic therapies is not well defined
and has not been reported routinely.8 The time to
re-treatment reported herein provides an estimate of
what would be expected to happen in clinical practice
because it is based on both the clinician’s and the
patient’s appreciation of disease severity and need for
re-treatment.
A review conducted by Koo and Lebwohl8 indicated
that the average duration of response with ciclosporin
is approximately 6 weeks and the median time to
relapse with methotrexate is approximately 10 weeks.
As a result, most patients are rarely free of disease,
which continues to place them at risk for adverse
events from drug therapy. Furthermore, withdrawal of
these generalized immunosuppressants has been asso-
ciated occasionally with rapid disease flares or conver-
sion of disease to more severe forms, such as pustular
or erythrodermic psoriasis, which can be life-threaten-
ing.2,3,25
Among patients who achieve clearing or near-
clearing of their psoriasis, the 10-month median time
to re-treatment observed with alefacept is markedly
longer than what we typically have observed in our
patients using traditional systemic therapies for
psoriasis (e.g. ciclosporin, methotrexate). The durable
responses in patients treated with alefacept are similar
to those we have observed in some patients after PUVA
therapy. In one long-term study, patients treated with
PUVA were without recurrence for 64 weeks.8 This
sustained effect has been linked to a cytotoxic action of
PUVA on activated lymphocytes in lesional skin.10,11
Alefacept also depletes lymphocytes, but in a selective
way, by removing mainly memory T cells.
Further evaluations of response duration are war-
ranted and were incorporated into the design of large,
randomized, placebo-controlled phase III studies of
alefacept. In these studies, patients who had at least a
75% improvement in their PASI scores were considered
to be in remission until they had relapsed to a 50%
improvement in PASI. The phase III results of alefacept
therapy for psoriasis26,27 support those found in this
study, namely that alefacept provides a long-term
remission of more than 7 months, consistent with its
mechanism of action in selectively depleting memory-
effector T cells.7,21,22
Note added in proof
In January 2003, alefacept was licensed by the US Food
and Drug Administration as Amevive.
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